Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Previous Vedolizumab Treatment and Fibroblast-Derived MMP13 with Nonresponse to Ustekinumab in Ulcerative Colitis Patients

  • By

  • Yuiko Tsuruta

  • Yoki Furuta

  • Masatoshi Nakashima

  • Cheng Pan

  • Shota Takano

  • Koichi Sakurai

  • Hideki Kitada

  • Kana Omoto

  • Taichi Matsuyama

  • Yoshinari Sakai

  • Suguru Chiyonaga

  • Kotaro Fukubayashi

  • Takashi Shono

  • Masakuni Tateyama

  • Kotaro Waki

  • Munenori Honda

  • Kenshi Matsuno

  • Akira Yamasaki

  • Hideaki Miyamoto

  • Ryosuke Gushima

  • Takehisa Watanabe

  • Katsuya Nagaoka

  • Hideaki Naoe

  • Yoshihiro Komohara

  • Yasuhito Tanaka

  • September 28, 2026

Share

Clinical Report: Previous Vedolizumab Treatment and Ustekinumab Nonresponse in UC

Overview

This study investigates the impact of prior vedolizumab treatment on the clinical response to ustekinumab in patients with ulcerative colitis. It identifies fibroblast-derived MMP13 as a potential biomarker associated with nonresponse to ustekinumab.

Background

Ulcerative colitis (UC) is a chronic inflammatory disorder with a complex treatment landscape. Despite the availability of multiple advanced therapies, many patients experience inadequate responses. This study evaluates the relationship between prior vedolizumab exposure and ustekinumab response.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • Previous treatment with vedolizumab may influence the effectiveness of ustekinumab in UC patients.
  • Fibroblast-derived MMP13 levels are associated with nonresponse to ustekinumab.
  • Clinical response and remission were evaluated at 2, 6, and 12 months post-ustekinumab initiation.
  • The study involved a multicenter, observational design across 11 institutions in Japan.
  • Eligibility criteria included patients aged 14-84 years who received at least one dose of ustekinumab.

Clinical Implications

Understanding the impact of prior vedolizumab treatment on ustekinumab response may guide therapeutic decisions in UC management. Monitoring fibroblast-derived MMP13 could help identify patients at risk for nonresponse.

Conclusion

The findings highlight the significance of treatment history in determining the efficacy of subsequent therapies in ulcerative colitis. Further research is warranted to validate these associations.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Frontiers in Medicine — Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study
  3. Characterizing Predictive Signaling Pathways for Response to Vedolizumab in Patients with Ulcerative Colitis
  4. Journal of Gastroenterology — Emerging Therapeutic Strategies for Inflammatory Bowel Disorders
  5. The New Gastroenterologist — Impact of Prior Anti-TNF Treatment on the Effectiveness of Subsequent Ulcerative Colitis Therapies
  6. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
  7. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension - PMC
  8. Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis | Journal of Gastroenterology | Springer Nature Link

Original Source(s)

Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis

  • by Yuiko Tsuruta, Yoki Furuta, Masatoshi Nakashima, Cheng Pan, Shota Takano, Koichi Sakurai, Hideki Kitada, Kana Omoto, Taichi Matsuyama, Yoshinari Sakai, Suguru Chiyonaga, Kotaro Fukubayashi, Takashi Shono, Masakuni Tateyama, Kotaro Waki, Munenori Honda, Kenshi Matsuno, Akira Yamasaki, Hideaki Miyamoto, Ryosuke Gushima, Takehisa Watanabe, Katsuya Nagaoka, Hideaki Naoe, Yoshihiro Komohara, Yasuhito Tanaka

  • September 28, 2026

Related Content

Correction: Defining post–colon capsule endoscopy colorectal cancer (pCCECRC)—an International Capsule Endoscopy Research (iCARE) group consensus statement

Racial disparities in the rate of same-admission cholecystectomy following biliary pancreatitis

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy